Advertisement
BIIB or VRTX or ZTS
Which Stock Would AI Choose? Biogen Inc. (BIIB) vs. Vertex Pharmaceuticals Incorporated (VRTX) vs. Zoetis Inc. (ZTS) Stock Comparison
Key Takeaways
- BIIB has shown strong recent momentum with shares up approximately 18% over the past 30 days and 29% over the past year, driven by Alzheimer's portfolio growth and upbeat earnings.
- VRTX maintains stability with a market cap exceeding $116 billion and positive pain management study results, though YTD returns lag slightly at around 0.3%.
- ZTS beat Q4 earnings expectations with revenue growth of 3%, but faces longer-term pressure with a 1-year return down about 23%, trading at a relatively attractive valuation.
- All three operate in animal or human health biotech/pharma, with BIIB and VRTX showing stronger recent relative performance versus broader markets.
- BIIB P/E around 21x contrasts with VRTX's 30x and ZTS's 20x, highlighting valuation sensitivities amid sector volatility.
- Recent market activity favors neurology-focused plays like BIIB for momentum traders, while ZTS appeals for defensive animal health exposure.
Introduction
This stock comparison examines BIIB, VRTX, and ZTS, three leaders in biotechnology and animal health. BIIB focuses on neurology therapies, VRTX on cystic fibrosis and emerging pain treatments, and ZTS on veterinary medicines. Investors seeking exposure to healthcare innovation, from human therapeutics to animal care, will find value in analyzing their relative performance, growth drivers, and market positioning. Amid recent biotech volatility and sector-specific catalysts, this review highlights key contrasts in momentum, valuation, and risk for informed trading and portfolio decisions.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) is a biotechnology firm specializing in therapies for neurological diseases, including multiple sclerosis and Alzheimer's treatments like Leqembi. With a market cap of about $27 billion and a trailing P/E of 21x, the stock has demonstrated robust recent market activity. Shares gained roughly 18% in the past 30 days and 29% over the past year, outperforming the S&P 500. This momentum stems from strong Q4 2025 earnings that beat estimates, with adjusted EPS of $1.99 and revenue of $2.28 billion, alongside optimistic 2026 guidance banking on Alzheimer's demand and pipeline progress. Sentiment has shifted positively due to expanding neurology products offsetting declines in older MS drugs, though longer-term 3- and 5-year returns remain negative amid patent pressures.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals Incorporated (VRTX) leads in cystic fibrosis treatments and advances in pain management and gene therapies, boasting a market cap over $116 billion and a trailing P/E near 30x. Recent performance shows modest gains, with shares up about 5-11% in recent monthly periods and flat to slightly positive 1-year returns around 0-6%. Key influences include promising JOURNAVX study results demonstrating effective non-opioid pain relief, enhancing its growth narrative beyond core CF franchise. Q4 earnings slightly missed at $5.03 EPS versus expectations, but revenue beat forecasts, supporting stability. Market sentiment reflects confidence in pipeline catalysts, though YTD returns trail peers amid broader biotech caution.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS) dominates animal health with vaccines, medicines, and diagnostics for companion and livestock animals, holding a $55 billion market cap and P/E around 20x. Recent stock behavior indicates short-term recovery with 3-4% monthly gains post-earnings, but 1-year returns down approximately 23% reflect longer-term weakness. Q4 2025 results exceeded expectations, posting $1.48 adjusted EPS and $2.39 billion revenue, up 3% year-over-year, driven by U.S. and international growth in parasiticide and dermatology portfolios. Sentiment is mixed due to divestments by some investors citing growth concerns, balanced by 2026 guidance for revenue of $9.83-10.03 billion and acquisitions like Neogen's genomics enhancing precision health offerings.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases over 25 top-performing AI trading bots curated for current market conditions from hundreds available, each trading thousands of tickers with diverse strategies, timeframes, and styles like swing, scalping, and hedging across stocks, ETFs, and crypto. These bots deliver impressive stats, including annualized returns up to +218% (e.g., volatility plays on USAR, SMR, CIFR), win rates of 70-95% (e.g., 94.92% on BIB biotech ETF), and profit factors exceeding 3.0 in sectors like aerospace (+98%), semiconductors (+113%), and infrastructure (+68%). Highlighted for low drawdowns and high consistency, they adapt to volatility via real-time signals from Signal, Virtual, and Brokerage Agents. Traders can explore and copy these for potential outperformance; visit Trending AI Robots to review live performance.
Head-to-Head Comparison
BIIB, VRTX, and ZTS span human neurology/biotech and animal health models, with BIIB and VRTX exposed to high-growth therapeutics versus ZTS's stable veterinary demand. Growth drivers differ: BIIB's Alzheimer's catalysts fuel momentum, VRTX's pain/CF pipeline offers durability, while ZTS relies on recurring animal care amid economic sensitivity. Recent momentum favors BIIB (18% 30-day), over VRTX and ZTS. Risks include pipeline setbacks for biotech duo and growth slowdowns for ZTS. Valuation sensitivity shows ZTS cheapest at 20x P/E, BIIB mid-range, VRTX premium. Market sentiment leans positive for human health innovation amid animal health's defensive trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently favors BIIB due to superior trend consistency, recent 18% monthly gains, earnings beats, and Alzheimer's catalysts positioning it ahead in relative performance. While VRTX offers pipeline stability and ZTS undervaluation, BIIB's momentum and neurology exposure suggest higher near-term probability of outperformance in the current biotech environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 0 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- BIIB’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 0 green, 5 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 5 bearish.
- VRTX’s TA Score: 4 bullish, 3 bearish.
- ZTS’s TA Score: 4 bullish, 4 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +2.53% price change this week, while VRTX (@Biotechnology) price change was +1.13% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +3.84% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.70%. For the same industry, the average monthly price growth was +8.17%, and the average quarterly price growth was +2.15%.
Reported Earning Dates
BIIB is expected to report earnings on Apr 29, 2026.
VRTX is expected to report earnings on May 04, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+3.70% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| BIIB | VRTX | ZTS | |
| Capitalization | 26B | 112B | 51.5B |
| EBITDA | 2.6B | 4.87B | 4.07B |
| Gain YTD | 0.773 | -2.682 | -2.319 |
| P/E Ratio | 20.18 | 28.80 | 20.33 |
| Revenue | 9.89B | 12B | 9.47B |
| Total Cash | 3.82B | 6.61B | 2.31B |
| Total Debt | 6.58B | 2.03B | 9.24B |
BIIB | VRTX | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 11 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 80 Overvalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 35 | 100 | |
SMR RATING 1..100 | 78 | 40 | 16 | |
PRICE GROWTH RATING 1..100 | 47 | 60 | 62 | |
P/E GROWTH RATING 1..100 | 14 | 53 | 85 | |
SEASONALITY SCORE 1..100 | 90 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (30) in the Pharmaceuticals Generic industry is somewhat better than the same rating for VRTX (80) in the Biotechnology industry, and is somewhat better than the same rating for BIIB (89) in the Biotechnology industry. This means that ZTS's stock grew somewhat faster than VRTX’s and somewhat faster than BIIB’s over the last 12 months.
VRTX's Profit vs Risk Rating (35) in the Biotechnology industry is somewhat better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry, and is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that VRTX's stock grew somewhat faster than ZTS’s and somewhat faster than BIIB’s over the last 12 months.
ZTS's SMR Rating (16) in the Pharmaceuticals Generic industry is in the same range as VRTX (40) in the Biotechnology industry, and is somewhat better than the same rating for BIIB (78) in the Biotechnology industry. This means that ZTS's stock grew similarly to VRTX’s and somewhat faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (47) in the Biotechnology industry is in the same range as VRTX (60) in the Biotechnology industry, and is in the same range as ZTS (62) in the Pharmaceuticals Generic industry. This means that BIIB's stock grew similarly to VRTX’s and similarly to ZTS’s over the last 12 months.
BIIB's P/E Growth Rating (14) in the Biotechnology industry is somewhat better than the same rating for VRTX (53) in the Biotechnology industry, and is significantly better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that BIIB's stock grew somewhat faster than VRTX’s and significantly faster than ZTS’s over the last 12 months.
| BIIB | VRTX | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 64% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 64% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 62% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 62% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 36% | 2 days ago 54% |
| Advances ODDS (%) | 4 days ago 57% | 5 days ago 63% | 5 days ago 52% |
| Declines ODDS (%) | 9 days ago 72% | 3 days ago 43% | 3 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 46% | N/A | 2 days ago 62% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 30% | 2 days ago 61% |
Advertisement
VRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRTX has been loosely correlated with CRSP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if VRTX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To VRTX | 1D Price Change % | ||
|---|---|---|---|---|
| VRTX | 100% | +1.27% | ||
| CRSP - VRTX | 37% Loosely correlated | +4.07% | ||
| EDIT - VRTX | 37% Loosely correlated | +4.03% | ||
| INCY - VRTX | 34% Loosely correlated | +2.62% | ||
| MRNA - VRTX | 34% Loosely correlated | -1.76% | ||
| MGTX - VRTX | 34% Loosely correlated | +6.65% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +2.81% | ||
| ELAN - ZTS | 52% Loosely correlated | +2.38% | ||
| PRGO - ZTS | 38% Loosely correlated | +3.33% | ||
| VTRS - ZTS | 37% Loosely correlated | +4.78% | ||
| HLN - ZTS | 37% Loosely correlated | +1.67% | ||
| PAHC - ZTS | 36% Loosely correlated | +5.92% | ||
More | ||||